Aptorum Gets Orphan Drug Tag For Repurposed Compound For Pediatric Cancer

 The FDA has granted Orphan Drug Designation to Aptorum Group Limited (NASDAQ: APM) SACT-1, a repurposed small molecule compound for Neuroblastoma.

• Aptorum Group plans to file an Investigational New Drug Application (IND) to commence a Phase 1b/2a trial for SACT-1 in 2022.

• Neuroblastoma is one of the most prevailing solid tumor cancers in children, representing 8% - 10% of all childhood tumors, accounting for around 15% of all cancer-related deaths in the pediatric population.

• Aptorum received its first US patent regarding SACT-1 repurposed drug for various cancers earlier this week.

• The SACT-1 invention provides a composition and method for treating or preventing the growth of cancerous tumors and/or delaying the onset of cancer from tumor-initiating cells.

https://finance.yahoo.com/news/aptorum-shares-rise-fda-orphan-134714476.html